DUSP4 and hepatocellular carcinoma: Moreover, dual specificity phosphatase 4 (DUSP4) as a negative regulator of sorafenib‐induced ferroptosis in hepatocellular carcinoma (HCC) modulated key ferroptosis‐related markers and possessed potential therapeutic strategies for overcoming sorafenib resistance [9].